Form 4: Serina Therapeutics CSO Exercises Options and Sells Shares Under Pre-Arranged Plan

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 6,500 shares of common stock for a significant gain as part of a pre-arranged trading plan.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc., executed a transaction on July 7, 2025.
• Moreadith exercised stock options to acquire 6,500 shares of common stock at an exercise price of $0.06 per share.
• Immediately following the exercise, Moreadith sold all 6,500 shares of common stock at a weighted average price of $5.67 per share.
• The sale price ranged from $5.55 to $5.94 per share.
• The transaction was conducted under a Rule 10b5-1 pre-arranged trading plan.
• Following these transactions, Randall Moreadith directly owns 0 shares of common stock.
• Moreadith still holds 508,186 stock options.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (option exercise and sale) under a pre-arranged plan, which is common for executive compensation. It does not inherently indicate positive or negative sentiment about the company's future, as it's a monetization event.

Positives

• The Chief Scientific Officer realized a substantial gain by exercising options at $0.06 and selling shares at a weighted average of $5.67.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned sale rather than a reaction to immediate market conditions.
• The stock options exercised were fully vested.

Negatives

• The Chief Scientific Officer sold all 6,500 shares acquired through the option exercise, reducing their direct common stock ownership to zero.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

This is a routine insider transaction, common for executives monetizing vested equity compensation. It does not provide broad industry-specific context.

Stakeholder Impact

• Shareholders: The sale by a Chief Scientific Officer could be perceived neutrally as a routine monetization of vested equity, or slightly negatively if interpreted as a lack of confidence, though the 10b5-1 plan mitigates this. The number of shares sold is relatively small compared to the total outstanding shares.

Key Dates

Recommendation

Keywords

Serina Therapeutics, SER, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Randall Moreadith, Chief Scientific Officer, Rule 10b5-1, Equity Compensation